Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Histochemistry

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44343   clinical trials with a EudraCT protocol, of which   7372   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    19 result(s) found for: Histochemistry. Displaying page 1 of 1.
    EudraCT Number: 2018-001552-36 Sponsor Protocol Number: 18SEIN08 Start Date*: 2020-09-09
    Sponsor Name:INSTITUT CLAUDIUS REGAUD
    Full Title: The use of FES-PET imaging as a tool to detect a possible reversion of Estrogen Receptor (ER)-α status in patients with metastatic breast cancer HER2 + and ERα neg treated with trastuzumab + pertuz...
    Medical condition: Metastatic breast cancer HER2 + and ERα neg.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults Gender: Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-000670-37 Sponsor Protocol Number: ESR-17-13332 Start Date*: 2019-05-09
    Sponsor Name:Radboud University Medical Center
    Full Title: Imaging tumor-infiltrating CD8+ T-cells in non-small cell lung cancer upon neo-adjuvant treatment with Durvalumab (MEDI4736).
    Medical condition: Patients with non-small cell lung carcinoma (NSCLC).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-000998-23 Sponsor Protocol Number: CL1-64315-003 Start Date*: 2019-09-19
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: A Phase I/II, open label, non-randomized study to evaluate safety, tolerability, pharmacokinetics and clinical activity of S64315 in patients with locally advanced or metastatic breast cancer in co...
    Medical condition: Locally advanced or metastatic breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10072740 Locally advanced breast cancer LLT
    20.0 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-000726-78 Sponsor Protocol Number: SPD488-401 Start Date*: 2004-12-02
    Sponsor Name:Shire Pharmaceuticals Group plc
    Full Title: A 24 Week Randomised Double Blind Placebo Controlled Study to Evaluate the Atrophogenic Potential of Eflornithine in the Treatment of Women with Excessive Facial Hair
    Medical condition: Facial Hirsutism in Women
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2014-002741-21 Sponsor Protocol Number: AAA-Ga-TOC-EU-01 Start Date*: 2014-10-23
    Sponsor Name:Advanced Accelerator Applications SA
    Full Title: Safety and tolerability of 68Ga-DOTATOC for injection in patients with proven gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs).
    Medical condition: Patients with proven gastro-entero-pancreatic neuroendocrine tumours (GEP-NETs)
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10062476 Neuroendocrine tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-004423-32 Sponsor Protocol Number: ACT17241 Start Date*: 2022-02-08
    Sponsor Name:Sanofi Aventis Recherche & Développement
    Full Title: Open-label, Phase 2 study, evaluating the efficacy and safety of tusamitamab ravtansine in non-squamous non-small-cell lung cancer (NSQ NSCLC) participants with negative or moderate CEACAM5 express...
    Medical condition: Non-squamous non-small-cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10079440 Non-squamous non-small cell lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) IT (Completed) FR (Completed) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-001273-81 Sponsor Protocol Number: EFC15858 Start Date*: 2019-12-17
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: Randomized, Open Label Phase 3 study of SAR408701 versus Docetaxel in Previously Treated metastatic Non-Squamous Non-Small Cell Lung Cancer patients with CEACAM5 positive tumors
    Medical condition: Non-small cell lung cancer metastatic
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing) HU (Prematurely Ended) DE (Completed) PL (Completed) PT (Completed) BE (Completed) ES (Prematurely Ended) GR (Completed) BG (Completed) FR (Trial now transitioned) IT (Completed) RO (Ongoing) LT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-021639-15 Sponsor Protocol Number: GC1008 Start Date*: 2011-07-07
    Sponsor Name:University Medical Center Groningen
    Full Title: Guiding GC1008 treatment of primary brain tumors by 89Zr-GC1008 PET imaging.
    Medical condition: High grade malignant glioma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-005696-17 Sponsor Protocol Number: 1645-CI-058 Start Date*: 2013-06-18
    Sponsor Name:Instituto de Investigacion Sanitaria La Fe
    Full Title: Multicenter, randomized, blinded clinical study comparing early use of total body moderate hypothermia plus topiramate or placebo in asphyxiated newborn infants evolving to moderate-to-severe hypox...
    Medical condition: Asphyxiated newborn infants evolving to moderate-to-severe hypoxic ischemic encephalopathy
    Disease:
    Population Age: Preterm newborn infants, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-002337-15 Sponsor Protocol Number: 99625945 Start Date*: 2020-09-16
    Sponsor Name:Oslo University Hospital
    Full Title: TOPICAL GENTAMICIN TREATMENT OF PATIENTS WITH EPIDERMOLYSIS BULLOSA DUE TO NONSENSE MUTATIONS (THE GENTELBULL STUDY)
    Medical condition: Epidermolysis bullosa caused by nonsense mutations or splice site mutations
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-002721-29 Sponsor Protocol Number: 08486 Start Date*: 2018-12-24
    Sponsor Name:Newcastle upon Tyne Hospitals NHS Foundation Trust
    Full Title: Randomised, double-blinded, placebo-controlled, adaptive design trial of the efficacy of acipimox in patients with Mitochondrial Myopathy
    Medical condition: Mitochondrial Myopathy
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2007-005668-28 Sponsor Protocol Number: AGAL06207 Start Date*: 2008-07-29
    Sponsor Name:Genzyme Europe BV
    Full Title: A Randomized, Multicenter, Multinational, Phase 3B, Open-Label, Parallel-Group Study of Fabrazyme (agalsidase beta) in Treatment-Naive Male Pediatric Patients with Fabry Disease Without Severe Symp...
    Medical condition: Fabry disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10016016 Fabry's disease PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male
    Trial protocol: GB (Completed) NL (Completed) PT (Prematurely Ended) DE (Prematurely Ended) CZ (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2019-003575-19 Sponsor Protocol Number: 4SC-202-4-2019 Start Date*: 2021-07-30
    Sponsor Name:4SC AG
    Full Title: A phase II, open label, multicenter study to investigate the efficacy and safety of domatinostat in combination with avelumab in patients with treatment-naïve metastatic Merkel Cell Carcinoma - the...
    Medical condition: treatment-naïve metastatic Merkel Cell Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10064025 Merkel cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) PL (Prematurely Ended) NL (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-000091-32 Sponsor Protocol Number: 20050225 Start Date*: 2006-10-25
    Sponsor Name:Amgen Inc.
    Full Title: A Randomized Phase 2 Trial of Double- Blind, Placebo Controlled AMG 706 in Combination with Paclitaxel, or Open- Label Bevacizumab in Combination with Paclitaxel, as First Line Therapy in Women wit...
    Medical condition: HER2 Negative Locally Recurrent or Metastatic Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IE (Prematurely Ended) ES (Completed) DE (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2019-003914-15 Sponsor Protocol Number: ACT16525 Start Date*: 2020-07-21
    Sponsor Name:Sanofi-Aventis Research and Development
    Full Title: Open-label, single-arm trial to evaluate antitumor activity, safety, and pharmacokinetics of SAR408701 used in combination with ramucirumab in metastatic, non-squamous, non–small-cell lung cancer (...
    Medical condition: Non-small cell lung cancer metastatic
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) BG (Completed) CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-005364-22 Sponsor Protocol Number: SOGUG-2021-IEC(VEJ)-4 Start Date*: Information not available in EudraCT
    Sponsor Name:Spanish Oncology Genitourinary Group (SOGUG)
    Full Title: Phase II non randomized clinical trial of NIVOLUMAB/IPILIMUMAB maintenance following first-line chemotherapy in unresectable locally advanced or metastatic urothelial cancer.
    Medical condition: unresectable locally advanced or metastatic urothelial cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10064467 Urothelial carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-001269-18 Sponsor Protocol Number: D-IVa/D-IVb Start Date*: 2013-12-19
    Sponsor Name:Universitätsklinikum Ulm (AöR)
    Full Title: A multicenter phase II study in patients with HER2-negative metastatic breast cancer and persisting HER2-negative circulating tumor cells (CTCs).
    Medical condition: Everolimus/ribociclib cohort (D-IVa): Postmenopausal female patients with hormone-receptor positive, HER2-negative metastatic breast cancer with HER2-negative circulating tumor cells (CTCs) and ind...
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-000415-87 Sponsor Protocol Number: 208467 Start Date*: 2019-12-11
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, alone or in combination with other agents, in HLA-A2+ Participants with NY-ES...
    Medical condition: Synovial sarcoma and Myxoid/Round Cell Liposarcoma (MRCLS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042863 Synovial sarcoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073137 Myxoid liposarcoma PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) NL (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) DE (Completed) IT (Trial now transitioned)
    Trial results: View results
    EudraCT Number: 2008-001436-12 Sponsor Protocol Number: CSET 2008/1378 Start Date*: 2008-07-04
    Sponsor Name:Institut Gustave Roussy
    Full Title: Phase 2 single-arm studies of Temozolomide in combination with Topotecan in refractory or relapsing Neuroblastoma and Other pediatric solid tumours.
    Medical condition: Neuroblastoma and Other pediatric solid tumours.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10066595 Neuroblastoma recurrent LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Ongoing) NL (Ongoing) AT (Completed) ES (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jun 14 19:13:24 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA